The Zhitong Finance App learned that a study found that the Trump administration's push to reduce US drug spending instead constituted a strong incentive for pharmaceutical companies to raise drug prices and reduce drug accessibility in other parts of the world.

The Zhitong Finance App learned that a study found that the Trump administration's push to reduce US drug spending instead constituted a strong incentive for pharmaceutical companies to raise drug prices and reduce drug accessibility in other parts of the world.